Recombinant humanized XVII type collagen and preparation method thereof
By expressing and optimizing the purification process in E. coli using genetic engineering technology, the problem of mass production of human type XVII collagen was solved, and recombinant collagen with good biocompatibility and high safety was prepared to promote hair follicle tissue activity and hair growth.
Patent Information
- Application Number
- CN202411154009.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-22
AI Technical Summary
Human type XVII collagen is present in very small amounts in the body, is difficult to extract, and cannot be mass-produced. Furthermore, animal-derived products pose immunogenicity and biosafety risks, which limits its research and application. Existing technologies make it difficult to achieve large-scale, high-density, and high-expression fermentation production and purification.
Using genetic engineering technology, recombinant humanized type XVII collagen was designed and expressed. Using Escherichia coli as the host cell, the amino acid sequence and purification process were optimized to achieve efficient expression and purification, thus preparing recombinant collagen with biocompatibility and safety.
The recombinant humanized type XVII collagen was expressed and purified efficiently, exhibiting good bioactivity in hair follicle repair and hair regeneration, suitable for large-scale industrial production, and without cytotoxicity.
Smart Images

Figure CN118994374A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of collagen and genetic engineering, and in particular to a recombinant humanized type XVII collagen and a preparation method thereof. Background Art
[0002] Collagen is one of the most important and abundant proteins in mammals. It is generally white, transparent, and unbranched fibrils. It is the basic support for skin and bones, accounting for 25% to 35% of the total protein. It is mainly distributed in human skin, blood vessels, bones, tendons, teeth, and cartilage. It is the main matrix and scaffold of these tissues, protecting and connecting various tissues, and plays an important physiological function in the body. Therefore, collagen can be widely used in industries such as medicine and cosmetics.
[0003] Human type XVII collagen is a transmembrane non-fibroblastic collagen, which is a homogeneous trimer composed of three identical α1 (XVII) chains, divided into three major structural domains: intracellular, transmembrane, and extracellular. Human type XVII collagen is a component of hemidesmosomes in cells, plays an important role in the function of epithelial cells-basement membrane, can regulate the adhesion, separation and development and differentiation of epithelial cells, and plays an important role in the differentiation and regeneration of keratinocytes. The content of human type XVII collagen in the human body is extremely low, and the content of type XVII collagen in animals is also extremely rare. The extraction is also very difficult and cannot be mass-produced. At the same time, animal-derived collagen products inevitably have immunogenicity and potential biosafety risks such as viruses and epidemics, and are not widely used. Limited by legal and ethical constraints, human type XVII collagen can only be used at the scientific research level, which has led to the fact that there are no commercialized type XVII collagen products from humans or other animals on the market, which further limits the research and application of human type XVII collagen. The main way to solve this problem now is to complete collagen through biotechnology such as genetic engineering.
[0004] The application of recombinant collagen requires that it can be fermented and purified on a large scale, with high density and high expression. Escherichia coli is an ideal expression host. However, as a eukaryotic organism, when a large amount of heterologous proteins are expressed and secreted, that is, when the intracellular biological resources are occupied in large quantities, Escherichia coli will inevitably regulate the expression of heterologous proteins accordingly. Its most prominent manifestation is actually the degradation of the expressed recombinant proteins. This is more prominent in the amino acid sequence of natural collagen that has not been mutated or modified. For specific types of recombinant proteins, determining a complete set of fermentation and purification processes to reduce degradation is the key technology to obtain recombinant collagen with a complete natural amino acid sequence, especially for high-density, high-expression fermentation production and purification for large-scale preparation and production. It is indispensable. Summary of the invention
[0005] The technical problem to be solved by the present invention is to utilize genetic engineering technology to recombinantly express a new recombinant humanized type XVII collagen, as well as a preparation method of the recombinant humanized type XVII collagen and an application of the recombinant humanized type XVII collagen in promoting hair growth.
[0006] Based on the above, the technical solution of the present invention is achieved as follows:
[0007] The present invention provides a recombinant humanized type XVII collagen, the amino acid sequence of the collagen is shown as SEQ ID NO.4-7.
[0008] The present invention also provides a nucleic acid molecule encoding the recombinant humanized type XVII collagen.
[0009] Furthermore, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.8-11.
[0010] The invention also provides a recombinant expression vector comprising the nucleic acid molecule.
[0011] The present invention also provides a host cell comprising the recombinant expression vector or expressing the collagen.
[0012] Furthermore, the host cell is Escherichia coli.
[0013] It should be noted that host cell refers to any cell type, which is susceptible to transformation, transfection, transduction, etc. of nucleic acid constructs or expression vectors containing polynucleotides of the present application. Host cell can be any cell useful in the production of recombinant humanized collagen of the present application. In order to produce recombinant collagen, nucleic acid encoding recombinant collagen can be separated and inserted into one or more vectors to further clone and / or express in host cells. Conventional techniques (e.g., by using oligonucleotide probes that can specifically bind to genes encoding recombinant collagen) can be easily separated and sequenced. The host cell refers to a cell into which exogenous nucleic acid has been introduced, including the offspring of such cells. Host cells include transformants and transformed cells, which include primary transformed cells and offspring derived therefrom, regardless of the number of passages. Offspring may not be completely identical to parental cells in nucleic acid content, but may contain mutations. It is well known that the method for introducing a vector into a host cell is, for example, using electrotransformation to introduce a vector into a host cell, and the method can also be transfection, microinjection technology, gene gun technology, liposome-mediated method, etc. The host cell is a prokaryotic cell or a eukaryotic cell. The host cell is selected from any one of Pichia pastoris, Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis. Preferably, the prokaryotic cell is Escherichia coli; preferably, the eukaryotic cell is Pichia pastoris.
[0014] The present invention also provides a method for producing the recombinant humanized type XVII collagen, which is characterized by comprising the following steps:
[0015] (1) culturing the host cell in a culture medium;
[0016] (2) Isolating the recombinant humanized type XVII collagen from the host cells.
[0017] The present invention also provides a composition, which includes the recombinant humanized type XVII collagen, or the recombinant humanized type XVII collagen encoded by the nucleic acid molecule, or the recombinant humanized type XVII collagen expressed by the recombinant expression vector, or the recombinant humanized type XVII collagen produced by the host cell, or the recombinant humanized type XVII collagen prepared by the production method.
[0018] The present invention also provides a product comprising the composition, which is a pharmaceutical composition, a medical device or a cosmetic.
[0019] Furthermore, the product is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printed artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.
[0020] Furthermore, the part of the cosmetic is not particularly limited, and can be the face, hands, legs, torso, etc. The form of the composition is not particularly limited, as long as the intended function can be achieved. For example, the composition is a solid, liquid or gel composition.
[0021] The present invention also provides the use of the composition in preparing pharmaceutical compositions, medical devices or cosmetics.
[0022] The present invention provides use of recombinant humanized type XVII collagen in preparing a drug for improving the activity of in vitro cultured hair follicle tissue or promoting hair growth.
[0023] Furthermore, the drug improves the microenvironment of hair follicle tissue, promotes the transformation of hair follicle tissue in the resting and degenerative phases into hair follicle tissue in the growth phase, thereby increasing the activity of cultured hair follicle tissue and significantly improving the survival rate of transplanted hair follicles.
[0024] Furthermore, the drug is contained in a hair follicle tissue culture fluid commonly used in clinical practice.
[0025] Furthermore, the drug promotes hair follicle growth via the Wnt / β-catenin signaling pathway.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] (1) The recombinant humanized type XVII collagen of the present invention is formed by a plurality of repeating units connected in series, and the repeating units are derived from the amino acid sequence of natural type XVII collagen, and thus has the advantages of good biocompatibility and high safety.
[0028] (2) The recombinant humanized type XVII collagen of the present invention has good biological activity for hair follicle repair and hair regeneration, can upregulate the Wnt protein in human hair follicle tissue, activate the downstream pathway of Wnt protein, and transform the hair follicle tissue in the resting phase and the degenerative phase into the hair follicle tissue in the growth phase, thereby promoting hair growth.
[0029] (3) The method for preparing recombinant humanized type XVII collagen of the present invention is simple and easy to operate, and is suitable for industrial large-scale production, and therefore has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 : Evaluation of cytotoxicity of recombinant humanized type XVII collagen.
[0031] Figure 2 : After 14 days of treatment with recombinant humanized type XVII collagen, the expression of Wnt3a protein in the cynochrome II group was detected by Western blotting and analyzed by ImageJ software compared with that in the control group.
[0032] Figure 3 : After 14 days of treatment with recombinant humanized type XVII collagen, the expression of β-catenin protein in the cynochrome II group was detected by Western blotting and analyzed by ImageJ software compared with that in the control group. DETAILED DESCRIPTION
[0033] The present invention is described below by way of examples to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto. The experimental methods described in the following examples are conventional methods unless otherwise specified; the medicinal materials and reagents described can be obtained from commercial channels unless otherwise specified; and the performance of products from different sources does not have a significant impact.
[0034] For those skilled in the art, the features, benefits and advantages of the present invention will become apparent by reading the contents disclosed in this specification.
[0035] Unless otherwise indicated, all percentages, fractions and ratios are calculated based on the total weight of the composition of the present invention. The term "mass content" herein may be represented by the symbol "%".
[0036] As used herein, "medical device" means instruments, equipment, apparatus, in vitro diagnostic reagents and calibrators, materials, and other similar or related items that are used directly or indirectly on the human body.
[0037] As used herein, "isolation" refers to separating the target polypeptide from the cultured host cells, for example, the host cells are lysed and the target polypeptide is purified. In the case where the purified target polypeptide carries a purification tag, such as a Trx or His tag, "isolation" also includes enzymatic removal of the Trx or His tag.
[0038] As used herein, "includes," "comprising," "including," "containing," "having," or other variations are intended to encompass non-exclusive inclusions, and no distinction is made between these terms. The term "comprising" means that other steps and ingredients that do not affect the end result may be added. The term "comprising" also includes the terms "consisting of" and "consisting essentially of." The compositions and methods / processes of the present invention may comprise, consist of, and consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, steps, or limitations described herein.
[0039] Example 1 Design of amino acid sequence of recombinant humanized type XVII collagen
[0040] In the present invention, the human natural type XVII collagen COL17 sequence is selected for screening and optimization. The sequence of human type XVII collagen is the NCBI reference sequence: XP_066518218.1 (SEQ ID No. 12), see https: / / www.ncbi.nlm.nih.gov / protein / XP_066518218.1. The details are as follows:
[0041]
[0042] The bold underlined part in the above sequence is the amino acid sequence selected by the present invention. The applicant has found through extensive research that the above sequence has strong water solubility, high recombinant expression yield, simple purification process, and achieves better hair follicle growth promoting effect than commercial collagen or other sequences in SEQ ID No.12.
[0043] The present invention is based in part on the following discovery: a polypeptide comprising at least 72 consecutive amino acid residues in SEQ ID No. 12 can have better biomaterial properties than commercial human collagen, so the sequences of several specific amino acid regions were tested:
[0044] HR-COL-1: GERGEPGPKGDPGTPGVKGDAGFPGLPGPPGPPGHPGQEG ARGPKGSAGEPGHDGPPGQRGREGPAGPRGEP (SEQ ID NO. 1).
[0045] HR-COL-2: GAPGTSGLPGTPGPQGFRGDAGDPGSKGERGPAGPPGAKG DQGEKGPRGATGEPGQPGPAGSAGEKGAKGSAGPGPDGEKGTRGDQGPIG LPGPRGPPGAQGDAGTPGSPGLQGPPGLPGTPGQPGAKGEPGEPGRV (SEQ ID NO. 2).
[0046] HR-COL-3: GPPGPAGPPGAPGPQGEPGHPGLPGEPGIGAPGPIGPPGSRG SPGPEGPPGPQGPLGPPGSEGPKGDAGVPGAPGIP (SEQ ID NO. 3).
[0047] The recombinant humanized type XVII collagen HR-COL-111 of the present invention is a three-repeat sequence of HR-COL-1, including 216 amino acids, and the basic repeating unit is: GERGEPGPKGDPGTPGVKGDA GFPGLPGPPGPPGHPGQEGARGPKGSAGEPGHDGPPGQRGREGPAGPRGEP (SEQ ID No. 1), which is a human collagen type XVII peptide segment.
[0048] The amino acid sequence of HR-COL-111 is as follows:
[0049] GERGEPGPKGDPGTPGVKGDAGFPGLPGPPGPPGHPGQEGARGPKGSAG
[0050] EPGHDGPPGQRGREGPAGPRGEPGERGEPGPKGDPGTPGVKGDAGFPGLPGP
[0051] PGPPGHPGQEGARGPKGSAGEPGHDGPPGQRGREGPAGPRGEPGERGEPGPK
[0052] GDPGTPGVKGDAGFPGLPGPPGPPGHPGQEGARGPKGSAGEPGHDGPPGQR
[0053] GREGPAGPRGEP (SEQ ID NO. 4).
[0054] The DNA sequence of HR-COL-111 is as follows:
[0055] (SEQ ID NO.8).
[0056] The recombinant humanized type XVII collagen HR-COL-222 of the present invention is a three-repeat sequence of HR-COL-2, including 414 amino acids, and the basic repeating unit is: GAPGTSGLPGTPGPQGFRGDA GDPGSKGERGPAGPPGAKGDQGEKGPRGATGEPGQPGPAGSAGEKGAKGSA GPPGPDGEKGTRGDQGPIGLPGPRGPPGAQGDAGTPGSPGLQGPPGLPGTPG QPGAKGEPGEPGRV (SEQ ID No. 2), which is a human collagen type XVII peptide segment.
[0057] The amino acid sequence of HR-COL-222 is as follows:
[0058] GAPGTSGLPGTPGPQGFRGDAGDPGSKGERGPAGPPGAKGDQGEKGPR
[0059] GATGEPGQPGPAGSAGEKGAKGSAGPPGPDGEKGTRGDQGPIGLPPGPRGPPG
[0060] AQGDAGTPGSPGLQGPPGLPGTPGQPGAKGEPGEPGRVGAPGTSGLPGTPGP
[0061] QGFRGDAGDPGSKGERGPAGPPGAKGDQGEKGPRGATGEPGQPGPAGSAGE
[0062] KGAKGSAGPGPDGEKGTRGDQGPIGLPGPRGPPGAQGDAGTPGSPGLQGPP
[0063] GLPGTPGQPGAKGEPGEPGRVGAPGTSGLPGTPGPQGFRGDAGDPGSKGERG
[0064] PAGPPGAKGDQGEKGPRGATGEPGQPGPAGSAGEKGAKGSAGPPGPDGEKG
[0065] TRGDQGPIGLPGPRGPPGAQGDAGTPGSPGLQGPPGLPGTPGQPGAKGEPGEP
[0066] GRV (SEQ ID NO.5).
[0067] The DNA sequence of HR-COL-222 is as follows:
[0068] GGCGCTCCTGGTACTTCTGGTCTGCCAGGTACCCCTGGTCCTCAGGGT
[0069] TTTCGTGGCGACGCGGGTGATCCGGGTTCCAAAGGCGAACGCGGTCCTGC
[0070] TGGTCCTCCTGGTGCCAAGGGTGACCAAGGCGAAAAAGGTCCGCGCGGC
[0071] GCAACTGGTGAACCAGGTCAACCGGGTCCAGCAGGTTCTGCTGGTGAAA
[0072] AAGGCGCAAAAGGCTCTGCAGGTCCGCCAGGTCCAGACGGTGAGAAAGG
[0073] TACCCGTGGTGATCAGGGTCCGATTGGTCTGCCTGGTCCACGTGGTCCGC
[0074] CTGGTGCTCAGGGTGATGCGGGTACCCCTGGTTCTCCAGGTCTGCAAGGT
[0075] CCACCAGGTCTGCCGGGTACCCCTGGTCAACCAGGTGCAAAAGGCGAAC
[0076] CGGGCGAACCGGGTCGTGTTGGTGCTCCAGGTACCAGCGGCCTGCCTGGT
[0077] ACTCCAGGTCCTCAAGGCTTCCGTGGCGATGCAGGTGACCCGGGTTCTAA
[0078] AGGTGAACGTGGTCCGGCAGGTCCACCGGGTGCTAAAGGCGATCAGGGT
[0079] GAAAAAGGTCCACGTGGTGCTACTGGCGAACCGGGCCAACCAGGTCCAG
[0080] CAGGTTCTGCCGGTGAAAAGGGCGCAAAAGGCTCTGCGGGTCCTCCAGGT
[0081] CCGGATGGTGAAAAAGGTACCCGTGGTGACCAGGGTCCTATTGGTCTGCC
[0082] GGGTCCTCGTGGTCCACCTGGTGCACAGGGTGATGCTGGTACTCCAGGTT
[0083] CTCCGGGTCTGCAGGGTCCTCCTGGTCTGCCAGGCACTCCGGGTCAACCA
[0084] GGCGCTAAAGGTGAACCAGGTGAACCAGGTCGTGTAGGTGCCCCAGGCA
[0085] CTTCTGGTCTGCCGGGTACTCCTGGCCCACAGGGTTTCCGTGGCGACGCT
[0086] GGTGACCCGGGTAGCAAAGGCGAACGTGGTCCAGCAGGTCCACCGGGTG
[0087] CAAAAGGTGATCAAGGTGAAAAAGGTCCGCGTGGTGCAACCGGTGAACC
[0088] GGGTCAGCCAGGTCCAGCAGGCTCTGCAGGTGAGAAAGGTGCAAAAGGT
[0089] TCCGCTGGCCCACCTGGTCCTGACGGTGAAAAAGGTACTCGTGGTGATCA
[0090] AGGCCCAATTGGTCTGCCTGGTCCTCGTGGTCCGCCAGGTGCACAAGGCG
[0091] ATGCAGGCACTCCGGGCTCTCCTGGTCTGCAAGGTCCTCCAGGTCTGCCA
[0092] GGTACCCCAGGTCAACCTGGTGCGAAAGGCGAACCAGGTGAACCGGGCC
[0093] GCGTC (SEQ ID NO. 9).
[0094] The recombinant humanized type XVII collagen HR-COL-333 of the present invention is a three-repeat sequence of HR-COL-3, including 231 amino acids, and the basic repeating unit is: GPPGPAGPPGAPGPQGEPGHP GLPGEPGIGAPGPIGPPGSRGSPGPEGPPGPQGPLGPPGSEGPKGDAGVPGAPG IP (SEQ ID NO.3), which is a human collagen type XVII peptide segment.
[0095] The amino acid sequence of HR-COL-333 is as follows:
[0096] GPPGPAGPPGAPGPQGEPGHPGLPGEPGIGAPGPIGPPGSRGSPGPEGPPG
[0097] PQGPLGPPGSEGPKGDAGVPGAPGIPGPPGPAGPPGAPGPQGEPGHPGLPGEP
[0098] GIGAPGPIGPPGSRGSPGPEGPPGPQGPLGPPGSEGPKGDAGVPGAPGIPGPPG
[0099] PAGPPGAPGPQGEPGHPGLPGEPGIGAPGPIGPPGSRGSPGPEGPPGPQGPLGP
[0100] PGSEGPKGDAGVPGAPGIP (SEQ ID NO. 6).
[0101] The DNA sequence of HR-COL-333 is as follows:
[0102] GGTCCGCCAGGCCCAGCAGGTCCACCAGGTGCACCAGGCCCACAGG
[0103] GTGAACCGGGCCACCCGGGCCTGCCGGGTGAACCGGGCATCGGCCGCC
[0104] AGGCCCGATTGGTCCGCCGGGCTCCCGCGGCTCTCCGGGCCCGGAAGGTC
[0105] CGCCGGGCCCGCAGGGTCCGCTGGGCCCGCCAGGTTCTGAGGGTCCTAAA
[0106] GGCGACGCTGGCGTTCCGGGTGCTCCTGGCATTCCTGGCCCGCCTGGTCC
[0107] TGCTGGCCCGCCGGGCGCACCGGGTCCGCAGGGCGAACCGGGTCATCCG
[0108] GGTCTGCCAGGTGAACCGGGTATCGGTGCACCAGGTCCGATCGGTCCGCC
[0109] AGGCTCTCGTGGTTCTCCTGGTCCGGAAGGTCCGCCGGGTCCGCAGGGTC
[0110] CGCTGGGTCCGCCTGGTTCCGAGGGCCCGAAAGGCGATGCCGGTGTTCCG
[0111] GGTGCTCCGGGTATTCCGGGTCCTCCTGGTCCTGCGGGTCCACCGGGTGC
[0112] ACCGGGTCCACAGGGTGAACCTGGTCACCCTGGCCTGCCTGGTGAGCCGG
[0113] GTATTGGTGCGCCAGGCCCGATCGGTCCGCCGGGCAGCCGTGGTTCCCCT
[0114] GGCCCGGAGGGTCCTCCGGGTCCGCAGGGTCCACTGGGTCCGCCGGGCTC
[0115] TGAAGGCCCGAAGGGCGATGCCGGCGTTCCGGGTGCGCCGGGCATCCCT
[0116] (SEQ ID NO.10)。
[0117] The recombinant humanized type XVII collagen HR-COL-123 of the present invention is a connection sequence of HR-COL-1, HR-COL-2 and HR-COL-3, including 287 amino acids, and is a type XVII peptide segment of human collagen.
[0118] The amino acid sequence of HR-COL-123 is as follows: GERGEPGPKGDPGTPGVKGDAGFPGLP GPPGPPGHPGQEGARGPKGSAGEPGHDGPPGQRGREGPAGPRGEPGAPGTSGLPGTPGPQGFRGDAGDPGSKGERGPAGPPGAKGDQGEKGPRGATGEPGQPGPAGSAGEKGAKGSAGPPGPDGEKGTRGDQ GPIGLPGPRGPPGAQGDAGTPGSPGLQGPPGLPGTPGQPGAKGEPGEPGRVGPPGPAGPPGAPGPQGEPGHPGLPGEPGIGAPGPIGPPGSRGSPGPEGPPGPQGPLGPPGSEGPKGDAGVPGAPGIP(SEQ ID NO.7).
[0119] The DNA sequence of HR-COL-123 is as follows:
[0120] GGCGAACGCGGCGAACCAGGTCCGAAAGGCGATCCGGGCACTCCGG
[0121] GCGTAAAAGGTGATGCCGGTTTTCCTGGCCTGCCAGGCCCTCCAGGTCCG
[0122] CCGGGCCACCCAGGCCAGGAGGGCGCCCGTGGCCCGAAAGGTTCCGCCG
[0123] GTGAACCGGGCCATGATGGTCCGCCGGGTCAGCGCGGTCGTGAAGGTCC
[0124] AGCGGGCCCACGCGGCGAACCGGGTGCGCCGGGCACTTCCGGTCTGCCG
[0125] GGTACTCCGGGTCCGCAAGGTTTCCGTGGTGACGCTGGTGACCCAGGCTC
[0126] CAAAGGCGAACGTGGTCCGGCTGGCCCGCCGGGCGCCAAAGGTGATCAA
[0127] GGTGAAAAGGGTCCTCGTGGTGCAACTGGCGAACCTGGTCAGCCGGGCC
[0128] CGGCAGGTTCCGCAGGTGAAAAAGGCGCAAAAGGTTCCGCGGGTCCGCC
[0129] GGGCCCGGATGGCGAAAAAGGTACCCGCGGCGATCAGGGTCCGATCGGT
[0130] CTGCCGGGTCCACGGCGGTCCTCCGGGTGCTCAGGGTGATGCTGGCACCCC
[0131] GGGTTCCCCAGGCCTGCAAGGCCCACCGGGTCTGCCGGGTACTCCAGGTC
[0132] AACCGGGTGCAAAAGGCGAACCGGGCGAACCAGGCCGTGTTGGTCCACC
[0133] GGGTCCGGCCGGCCCTCCAGGCGCGCCGGGTCCACAGGGTGAACCGGGC
[0134] CATCCTGGTCTGCCAGGCGAGCCGGGTATTGGCGCCCCGGGTCCGATCGG
[0135] CCCGCCAGGCTCCCGTGGCTCTCCAGGCCCAGAAGGCCCTCCTGGCCCGC
[0136] AGGGTCCGCTGGGTCCACCGGGCTCCGAAGGCCCGAAAGGCGATGCGGG
[0137] TGTGCCGGGCGCCCCAGGCATCCCG (SEQ ID NO. 11).
[0138] The DNA sequences of the above collagen proteins are all codons of recombinant genes optimized based on codon preference and expression capacity in an Escherichia coli expression host using the Exp Optimizer codon optimization tool.
[0139] Table 1 Sequence list of recombinant humanized type XVII collagen
[0140] Recombinant humanized type XVII collagen Amino acid sequence DNA sequence HR-COL-111 SEQ ID NO.4 SEQ ID NO.8 HR-COL-222 SEQ ID NO.5 SEQ ID NO.9 HR-COL-333 SEQ ID NO.6 SEQ ID NO.10 HR-COL-123 SEQ ID NO.7 SEQ ID NO.11
[0141] Example 2 Construction and expression of recombinant humanized type XVII collagen expression vector
[0142] The gene sequence of collagen is shown in SEQ ID NO.8-11, and was submitted to Sangon Biotech (Shanghai) Co., Ltd. for full gene synthesis.
[0143] The same method as in Example 2 of the patent CN118324899B authorized by the applicant was used to construct vectors and express and purify target collagens HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123. The specific steps are as follows:
[0144] (1) The DNA fragments of SEQ ID NOs. 8-11 were cloned and amplified by PCR, and the target genes were recovered by agarose gel electrophoresis. Using the EcoRI and NotI restriction sites added to the primers, the corresponding restriction endonucleases were added to cut the gene fragment into sticky ends, and the fragments were co-incubated with the pPIC9K expression vector (purchased from Thermo Fisher Scientific) treated with the corresponding restriction enzymes, and T4 DNA ligase (TaKaRa, catalog number 2011A) was added. The fragments were connected at 4°C for 12 hours and transformed into Escherichia coli DH5α (purchased from Sangon Biotech (Shanghai) Co., Ltd.); white spot clones were selected by screening on ampicillin sodium-LB plates, plasmids were extracted by alkaline lysis method of molecular cloning, and positive clones were identified by restriction enzyme digestion and PCR methods. Finally, sequencing confirmed that the recombinant plasmids contained the correct gene sequence reading frame, and pPIC9K-HR-COL-111, pPIC9K-HR-COL-222, pPIC9K-HR-COL-333 and pPIC9K-HR-COL-123 recombinant expression vectors were successfully constructed, and sequenced by Sangon Biotech (Shanghai) Co., Ltd.
[0145] (2) The correct pPIC9K-HR-COL-111, pPIC9K-HR-COL-222, pPIC9K-HR-COL-333 and pPIC9K-HR-COL-123 expression vectors were transformed into Escherichia coli BL21 (DE3) (purchased from Sangon Biotech (Shanghai) Co., Ltd.), and single-plaque clones were selected using ampicillin sodium-LB plates. They were cultured overnight in 5 ml LB medium, transferred at a ratio of 1:100, and cultured in a shake flask at 37°C until OD600 was 0.5. IPTG stock solution was added at a ratio of 1:5000, and cultured at 20°C for 8 hours. The cells were collected by centrifugation and stored at -20°C or immediately proceeded to the next purification step.
[0146] (3) Wash the mixed bacterial precipitate with PBS buffer, resuspend about 500 ml of bacterial solution in 20-40 ml volume, use lysozyme and Triton X-100 to help lyse the bacteria, sonicate in an ice-water mixture for 60 min, centrifuge at 12000 rpm / min for 20 min, and collect the supernatant. At this time, the solution contains a large amount of the target recombinant humanized type XVII collagen HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123.
[0147] (4) Ammonium sulfate precipitation and graded salting out were used for preliminary purification. After exploring the saturation of ammonium sulfate, the optimal saturation of ammonium sulfate salting out was 20%. The nickel ion affinity column (Ni-NTA His-Bind Resin) was washed with PBS buffer, and then the column material and the above-mentioned desalted and purified solution were mixed and co-incubated, and gently shaken at room temperature or on ice for 30 minutes, and then loaded onto the column, and the impurity protein was washed with a PBS solution containing 15mM imidazole, and pure type XVII collagen was left on the column. An appropriate amount of Prescission Protea se protease with a His tag was added to the column, and gently shaken at room temperature or on ice for 2 hours to release the type XVII collagen protein from the column, and eluted with PBS solution, so that high-purity recombinant humanized type XVIII collagen HR-COL-111 of SEQ ID NO.4, recombinant humanized type XVII collagen HR-C OL-222 of SEQ ID NO.5, recombinant humanized type XVII collagen HR-COL-333 of SEQ ID NO.6 and recombinant humanized type XVII collagen HR-COL-433 of SEQ ID NO.7 were obtained. NO.8 recombinant humanized type XVII collagen HR-COL-123 was freeze-dried for later use.
[0148] Example 3 Evaluation of cytotoxicity of recombinant humanized type XVII collagen
[0149] HeLa cells grown to 80% of the bottom area of the culture flask were taken, digested with 0.25% trypsin, and made into a cell density of 1×10 5 / mL of cell suspension. Take 100μL of cell suspension and inoculate it in a 96-well culture plate and culture it in an incubator at 37°C and 5% CO2 saturated humidity. After 24 hours of cell culture, aspirate the complete culture medium. Add a recombinant humanized type XVII collagen solution diluted with high-glucose DMEM medium to the experimental group at a concentration of 100μg / ml (3 replicates for each concentration), the control group is cells cultured in DMEM medium, and the blank group is DMEM medium without cells. Continue to culture in an incubator at 37°C and 5% CO2 saturated humidity for 24 hours. Add 10μL of CCK-8 reagent to each group, incubate in the cell culture incubator for 2 hours, and use an enzyme-linked immunosorbent assay to measure the absorbance value (OD value) of each well at a wavelength of 450nm. Calculate the cell survival rate according to the mean absorbance of each group according to the following formula:
[0150]
[0151] In this example, the positive control group was a commercially available recombinant type XVII collagen sample solution, which was added to the cell culture medium at 100 μg / ml, with 3 parallel samples in each group.
[0152] The experimental results are as follows Figure 1 As shown, the cell viability of each experimental group was above 100%, indicating that the recombinant humanized type XVII collagen HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123 prepared by the present invention had no cytotoxicity and good safety.
[0153] Example 4 Effect of Type VII Collagen on Wnt / β-catenin Signaling Pathway in Human Scalp Hair Follicle Tissue Cultured in Vitro
[0154] (1) Main reagents and drugs:
[0155] The collagens prepared in Example 2: HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123; rabbit anti-human Wnt3a monoclonal antibody, rabbit anti-human β-catenin monoclonal antibody, β-actin (Jin Kairui), and RPM11640 culture medium (Thermo Fisher).
[0156] (2) Experimental steps:
[0157] Take the discarded human scalp hair follicles after hair transplantation, and immediately place them in a sterile centrifuge tube filled with physiological saline after obtaining the ex vivo specimens. Separate the hair follicles under a microscope, move the separated hair follicle tissue to a new PBS culture dish, and wash it three times with fresh PBS. Use a 2mL pipette to carefully aspirate and discard the PBS washing solution under a microscope.
[0158] Collagen HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123 were dissolved in serum-free RPMI1640 culture medium and diluted to 50 μg / ml. Hair follicle tissue was inoculated into a six-well plate, 12 wells of which were added with culture medium containing HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123 (final concentration of 50 μg / ml) as the collagen experimental group, and 3 wells without drug addition were used as the control group. The cells were cultured in a cell culture incubator at 37°C and 5% CO2.
[0159] After 14 days, the control group and collagen experimental group were taken for Western blot detection, and the protein was extracted with RIPA lysis buffer, and the protein concentration was determined by BCA protein kit. The protein was denatured at 96℃ for 8min, 8μL of sample was added to each well, and Tris-SDS polyacrylamide gel was vertically electrophoresed and transferred to PDVF membrane, blocked with 6% skim milk powder at room temperature for 1.5h, and Wnt3a antibody (1:2000), β-catenin antibody (1:2000), and β-actin (1:2000) were added, and the membrane was incubated at 4℃ overnight, the primary antibody was washed off, and 1:1000 goat anti-rabbit secondary antibody was added; the secondary antibody was washed off, and the ECL luminescent agent imaging system was used for imaging, and the average optical density (OD) was analyzed by ImageJ software.
[0160] (3) Experimental results and conclusions
[0161] like Figure 2-3 As shown, compared with the control group, the collagen experimental group can significantly upregulate the Wnt protein in the human hair follicle tissue cultured in vitro and activate the downstream pathway of the Wnt protein. It can be seen that the recombinant humanized type XVII collagen HR-COL-111, HR-COL-222, HR-COL-333 and HR-COL-123 of the present invention can transform the hair follicle tissue in the resting phase and the degenerative phase into the hair follicle tissue in the growth phase by acting on the Wnt / β-catenin signaling pathway.
[0162] The above describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and the specification only describe the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention. The scope of protection claimed by the present invention is defined by the attached claims and their equivalents.
Claims
1. A recombinant humanized type XVII collagen, characterized in that: The amino acid sequences of the collagen are shown in SEQ ID NO.4-7 respectively.
2. A nucleic acid molecule encoding the recombinant humanized type XVII collagen according to claim 1.
3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequences of the nucleic acid molecules are shown in SEQ ID NOs. 8-11 respectively.
4. A recombinant expression vector comprising the nucleic acid molecule of claims 2-3.
5. A host cell comprising the recombinant expression vector according to claim 4 or expressing the collagen according to claim 1.
6. The host cell according to claim 5, characterized in that The host cell is Escherichia coli.
7. The method for producing recombinant humanized type XVII collagen according to claim 1, characterized in that: The method comprises the following steps: (1) culturing the host cell according to claim 5 in a culture medium; and (2) isolating the recombinant humanized type XVII collagen according to claim 1 from the host cell.
8. A composition, characterized in that The composition comprises the recombinant humanized type XVII collagen according to any one of claims, or the recombinant humanized type XVII collagen encoded by the nucleic acid molecule according to any one of claims 2-3, or the recombinant humanized type XVII collagen expressed by the recombinant expression vector according to claim 4, or the recombinant humanized type XVII collagen produced by the host cell according to any one of claims 5-6, or the recombinant humanized type XVII collagen prepared by the production method according to claim 7.
9. A product comprising the composition according to claim 8, characterized in that The product is a pharmaceutical composition, a medical device or a cosmetic.
10. Use of the composition according to claim 8 in the preparation of a drug for increasing hair follicle activity or promoting hair growth.
Citation Information
Patent Citations
Human collagen 17-type polypeptide and production method and application thereof
CN110845603A
Recombinant XVII type collagen Pro.C17 as well as preparation method and application thereof
CN117756926A
Recombinant XVII type humanized collagen as well as preparation method and application thereof
CN118324899A
Cited By
Method for fermenting recombinant humanized collagen by using escherichia coli and application of recombinant humanized collagen
CN119431561A
Recombinant humanized I-type collagen based on expression and purification in escherichia coli and application of recombinant humanized I-type collagen
CN119552240A
A recombinant humanized type I collagen protein expressed and purified in Escherichia coli and its application
CN119552240B
Recombinant A type humanized XVII type collagen as well as construction and application thereof
CN120248093A
Recombinant humanized type a xvii collagen and its construction and use
CN120248093B
